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that the number of glioma patients may have increased over the past decade. Current thera-
peutic options for glioma patients include tumor resection, chemotherapy, and concomitant
radiation therapy with an average survival of approximately 16 months. The rapid progression
of gliomas has spurred the development of novel treatment options, such as cancer gene ther-
apy and oncolytic virotherapy. Preclinical testing of oncolytic adenoviruses using glioma
models revealed both positive and negative sides of the virotherapy approach. Here we pre-
sent a detailed overview of the glioma virotherapy field and discuss auxiliary therapeutic stra-
tegies with the potential for augmenting clinical efficacy of GBM virotherapy treatment.
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CRAd for glioma therapy 215Glioma as a target for gene therapyGlioblastoma Multiforme (GBM) is the most common pri-
mary brain cancer in humans. In the cancer hierarchy, pa-
tients with brain tumors represent a relatively small cohort
with an estimated 500,000 total cases diagnosed, and
20,000 e deaths reported annually. The incidence of GBM
has risen1 lately in Europe and North America with 3.19
cases per 100,000 patients diagnosed yearly2 in the US
alone. While current GBM diagnostic techniques have
improved tumor detection sensitivities, the average sur-
vival is a dismal 16e20 months, and less than 20% of GBM
patients survive more than 5 years after diagnosis.3
Histologically GBM can be defined as a tumor of astro-
cytes, which represent 80% of normal brain tissue. Astro-
cytomas are characterized based on several parameters,
such as tumor localization in the brain, molecular features
and invasiveness. According to the WHO classification,
there are 4 different stages of brain cancer progression
(where stage 4 is the most advanced), based largely on cell
differentiation markers. Transition of astrocytoma grade
2egrade 4 (GBM) is associated with changes in cellular
signaling pathways such as TP53, EGFR, PTEN, etc. Also, it
is well documented that during this transition astrocytomas
incur genomic deletions (IDH1, PTEN), which activate
various signaling pathways responsible for new aggressive
phenotypes. Based on such genomic rearrangements Ver-
haak et al. grouped gliomas into mesenchymal, classical,
neural, and proneural subtypes.4 Each glioma subtype is
characterized by a specific gene expression pattern that
ultimately determines the tumor behavior.
Another constituent of glioma tumors is glioma stem
cells (GSCs), or cancer stem cells, which demonstrate the
ability to form tumors upon intracranial injection. Cancer
stem cells are capable of forming spherical structures
in vitro, called neurospheres, which may account for both
chemo- and radioresistance of glioma tumors in patients.5,6
Stem cell properties have been ascribed to those cells
based on their capability to maintain the tumor cell popu-
lation, which implicates them in tumorigenesis and tumor
recurrence mechanisms.7,8 It remains unclear whether the
differentiation of cancer stem cells into a tumor requires
environmental factors to accelerate tumorigenesis. How-
ever, scientific reports in the last 10 years suggest that one
of the most devastating human cancers, such as glioma,
originates from neural progenitor cells with a strong pro-
liferative capability. Moreover, infection of progenitor cells
with cytomegalovirus (CMV) significantly promotes pro-
gression of glioma in mouse experimental models of the
disease.9 Additionally, a growing body of evidence suggests
that both immunotherapeutic10 and chemotherapeutic11
approaches targeting CMV improve overall patient sur-
vival. This data points towards CMV as a new potential
etiological factor of GBM progression, representing an ideal
target for gene therapy.
Gene therapy is an alternative approach for
glioma therapy
Treatment of extremely vascularized tumors, such as gli-
omas is very challenging. The standard of GBM patient careincludes surgical resection, radiation, and chemotherapy.
Although, temozolomide, bevacizumab and carmustine
provide longer survival times, neither drug prevents glioma
recurrences, mainly due to the activation of a mechanism
that enables immune evasion and causes drug resistance.
For instance, a recent study suggests that bevacizumab
treatment promotes tumor invasion via activation of
MMP2,12 while other scientific reports implicate activation
of the mTOR pathway.13,14 This is one of the key pathways
responsible for the induction of cellular autophagy, which
negatively affects glioma cells and triggers an inflammatory
response. The fact that glioma stem cells (GSCs) cannot be
targeted and destroyed by chemotherapy and radiation
implicates them in the observed resistance of gliomas to
traditional therapies, which makes treatment of the dis-
ease extremely challenging. Therefore, there is an urgent
need for a new therapeutic approach with an improved
efficacy that would target both the tumor cell, and the
stem cell components of gliomas. Such new therapeutic
approaches should target GSCs, while simultaneously
comprising the existing therapeutic options, such as
ionizing radiation and temozolomide. Since conventional
chemotherapeutic agents exhibit strong toxicity towards
cancer cells, and in most cases do not spare normal cells,
cancer gene therapy seems promising with regard to its
higher potential specificity and efficacy. Cancer gene
therapy, therefore, is a unique approach capable of utiliz-
ing a multifunctional platform for tumor targeting, imaging,
and gene delivery. This approach is based on the design of
vectors capable of delivering any payload to the tumor cells
using various injection routes. Viral vectors exhibit great
advantages over non-viral means of gene delivery owing to
their natural capability of highly efficient cell attachment
and entry (perfected in the course of viral evolution) as a
crucial part of gene delivery mechanism, and provide the
highest level of transgene expression as part of the viral
replication cycle, resulting from high amplification of
transgene expression (for replication-competent vectors).Adenoviral vectors: Exclusive and not
exclusive for glioma therapy
In the late 1950’s Levy and Rowe discovered a new agent
capable of passing through bacteria retention filters and
infecting mammalian cells.15,16 It took more than 40 years
after discovery of adenovirus (Ad) to accumulate knowl-
edge about adenoviral biology critical for the develop-
ment and advancement of the Ad-based vector technology
for tumor targeting. Today, human Ad-based vectors have
been recognized as a major tool for gene therapy with
more than 100 various adenoviral vectors developed for
glioma targeting. The attractiveness of adenoviruses,
especially the most studied human serotypes 2 and 5, for
glioma targeting applications is largely based on the
knowledge that some parts of the viral genome (impli-
cated in modulation of the host immune and inflammatory
responses), can be omitted without affecting viral repli-
cation, assembly, and can be replaced with a gene of in-
terest for therapeutic purposes. Furthermore, currently
available capsid-modified Ad vectors can recognize a large
variety of cell surface molecules as primary and secondary
216 I.V. Ulasov et al.receptors allowing efficient infection of both quiescent
and rapidly proliferating tumor cells independently from
the expression of the Ad native primary coxsackie-
adenovirus receptor (CAR). The ability to use com-
plementing and non-complementing cells of mammalian
origin allowing human Ad propagation to high titers in
culture, represents an important biotechnological advan-
tage of using these vectors for gene and cancer gene
therapy (Fig. 1). Given that many self-amplifying, or
“replication-competent” Ad vectors with cancer-selective
replication properties, also known as Conditionally Repli-
cative Adenoviruses vectors (CRAds), exhibit strong
oncolytic anti-glioma effects, those vectors are the pri-
mary focus of our review.
Adenovirus generation (“rescue”) systems
Various strategies have been proposed to design
replication-competent Ad vectors. To generate or “rescue”
a replication-competent vector, a two-phase approach is
commonly used. In the first phase, all necessary Ad genetic
modifications/alterations are made in the viral genome.
This includes initial genetic manipulations within one or
more genomic regions (typically E1, E3, E4, hexon, or Fiber
genes) in the context of a small “shuttle” plasmid using
conventional DNA cloning technologies, followed by
sequential transfer of the resulting modifications to a large
size intermediate (“backbone construct”) and/or a full-size
genome (“rescue vector”) by homologous recombination
(HR) in mammalian cells or bacteria (E. coli strain BJ5183).
Those modifications typically involve mutations in Ad capsidFigure 1 CRAd replication cycle resulting in target cell oncoly
mediated cell killing starting with binding of a CRAd particle to
viral internalization via the endosome pathway and subsequent cap
(still complexed with core proteins) to the nucleus, where the reco
for viral proteins. Following mRNA transport into the cytoplasm and
particles are assembled from capsomers in the nucleus, following n
released form the infected cells via a replication-dependent (onco(structural) proteins, replacement or incorporation of pro-
moter elements (constitutive or tumor-specific), along with
the transgene(s) of interest. In the second phase, a line-
arized form of recombinant full-size genomic DNA is
transfected into mammalian (helper HEK293) cells, where
the Ad genome termini, formed upon restriction digestion
and release of the vector’s plasmid (bacterial) portion,
create a replication fork to initiate DNA replication
(doubling), followed by intracellular production of viral
mRNAs, proteins, and the assembly of viral particles. Most
recently, Stanton et al. proposed to utilize a high
throughput AdZ rescue system that allows a direct, single-
step insertion of PCR products or synthesized sequences
into the Ad genome and obviates the need in vector line-
arization prior to transfection into packaging cells.17Glioma-associated alterations in signaling
pathways offer molecular strategies for
engineering anti-glioma CRAds
The rapidly growing body of knowledge on signaling path-
ways activated in glioma cells offers an important insight
into potential molecular strategies for increasing antitumor
efficacy of CRAd vectors. Genetic analysis of clinical sam-
ples demonstrates aberrations in the PTEN, p16INK4A,
EGFR, and P53 signaling pathways. About 80% of glioblas-
toma specimens presented in The Cancer Genome Atlas
(TCGA) possess aberrations in CDKN2A and Rb pathways.
The latter regulate astrocytoma survival and tumor cell
proliferation.18,19 Furthermore, deletions of the PTEN genesis. A schematics illustrating the basic mechanism of CRAd-
a tumor-specific cell surface receptor(s). This is followed by
sid disintegration and trafficking of the released genomic DNA
mbinant genomic DNA is transcribed to produce mRNAs coding
its translation into virus-specific proteins, adenoviral progeny
uclear import of the Ad structural proteins. Ad progeny is then
)lytic mechanism.
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samples exhibit EGFR amplification, and about 11% of
samples reveal mutations in P53 and IDH1 genes.20
Ad capability for selective replication in gliomas is
determined by genetic information encoded by the self-
amplifying Ad genome. The first anti-glioma CRAds were
designed using deletion of Immediate Early (E1) viral genes
such as E1B-55K, which blocked vector replication in
normal, but not in cancer cells. The glioma-specific onco-
lytic vector, referred to as ONYX105 or dl1520, was
designed to replicate in the p53 deficient tumor cells with
functional defects in p53 tumor suppressor signaling21 and
induce non-apoptotic cell death during viral infection.22
However, over the past several decades, multiple scienti-
fic reports have evidenced that dl1520 can also replicate in
normal (non-cancer) cells, suggesting involvement of a p53-
independent replication mechanism.23,24
The delta24 CRAd vector (also known as dl922-947, or
ONYX-838) was constructed by introducing a 24 bp deletion
in the E1A gene. In the course of Ad infection, the E1A-
encoded protein binds to the cellular tumor suppressor
protein retinoblastoma (pRb) to displace transcription
factor E2F from the intracellular E2F/Rb complex, thereby
controlling the intracellular pool of free E2F. The release of
E2F results in entry of the infected cell into the S-phase, a
prerequisite for Ad DNA replication. The delta24 Ad mutant
can replicate in actively dividing cells that have an aberrant
G1-S checkpoint.25 While normal cells do not support
replication of the delta24 CRAd, the virus is effective
against U251 and U87 glioma cells at doses of 10 infectious
units per cell (iu) in vitro, and 100 iu per cell in vivo.26
Recently, Gomez-Manzano et al. reported a new vector
E1A-E1B (CB1), which combines both delta24, and E1B-55K
deletions. Although the CB1 vector demonstrates a more
robust replication, resulting in greater cytotoxicity in vitro
than delta24, intracranial injection of the double mutant
vector into mice results in the same animal survival rates
(pZ 0.28, Mean percent survival is 59 vs. 51 days) as those
found for delta24 CRAd.27
Clinical use of dl1520, delta24, or the double mutant
CB1 as individual vectors (monotherapy) for gene therapy
applications demonstrated limitations for each of those
agents. For instance, Geoerger et al demonstrated that 5
consecutive intratumoral injections of human xenografts
with dl1520 are not sufficient to prevent tumor progression
in mice. This observation suggests that additional modifi-
cations are required to create a more specific and effica-
cious CRAd agent. Therefore, combinations of various
strategies based on utilization of molecular features of
glioma tumors are needed to design a potent anti-glioma
therapeutic CRAd.Figure 2 Retargeting of adenoviral particles to an alternate
receptor improves targeting specificity of replication-
competent adenoviral vectors.Improving Ad targeting and internalization
It is unclear if incorporation of capsid modifications into
recombinant Ad genomes that could potentially affect
therapeutic potency of the vector is always justified, i.e.
whether those modifications are really necessary to achieve
successful gene targeting. For example, to treat prostate
cancer Freytag and collaborators used a capsid-unmodified
oncolytic adenovirus for successful delivery of cytokinesand two suicide genes.28 On the contrary, given that glioma
cells express low levels29 of primary Ad5 receptor (Cox-
sackie-and-adenovirus receptor, CAR), payload delivery to
the tumor cells via capsid-unmodified viral particles might
be inefficient, and could induce normal cell toxicity due to
CAR expression on healthy cells (Fig. 2). This evidence ex-
poses one of the major limitations of Ad vectors, i.e. the
intrinsically low efficiency of tumor cell transduction.
To increase Ad vector specificity several strategies have
been developed. One of them involves Ad serotype
chimerism. Currently, over 100 types/serotypes of the
Adenoviridae family have been characterized. Those
comprise 5 genera, capable of infecting humans and a large
number of animal species. Human Ad species belong to the
Mastadenovirus genus comprising 57 characterized sero-
types (Ad1eAd57) and 7 distinct species/groups (A-G) based
on the variety of serotype-specific and group-specific
characteristics. An important group-specific characteristic
is the ability to recognize common (group-specific) re-
ceptor(s) located on the surface of target cells, such as a
glioma cells. Adenovirus type 5 of group C has been a pre-
dominant vector used for gene therapy applications.
Adenoviral particles transduce target cells by a mecha-
nism involving a direct initial interaction between the fiber
protein of the Ad capsid, and the primary Ad receptors on
the surface of tumor cells. It has been suggested that
Desmoglein 2 (DSG2) and CD46 molecules represent such
native primary receptors of the Ad group B2 serotypes
(Ad11, 14, 34 and 35 and others), or group B1 serotypes
(Ad3, 7, 16, 21, 50 and others), respectively. Therefore,
replacing the Ad5 fiber knob (C-terminal) domain, or the
knob-shaft region of the wild type Ad5 with those of other
serotypes allows potential retargeting of adenoviral parti-
cles from CAR (Ad5 native receptor) to alternate (other
serotype-specific) receptors such as DSG2, CD46 etc. In line
with this, Nandi et al.,30 Wohfahrt et al.31 and Li et al.32
independently demonstrated that pseudotyping Ad5 parti-
cles with fibers from serotypes 3, 35 or 11 significantly
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type (WT) Ad5 both in vitro, and in vivo.
The lack of the CAR receptor on glioma cell surface is
the reason for the poor gene transfer in those cells by re-
combinant Ad vectors with an unmodified fiber. Therefore,
it would be valuable to improve Ad target cell transduction
for therapeutic uses. Retargeting of particles to alternate
receptors abundant on the surface of glioma cells may
circumvent their intrinsically low CAR expression. One
group of such surface molecules characteristically
expressed on glioma cells is represented by integrins. It has
been shown that insertion of RGD-4C ligand (cyclic peptide)
into the fiber protein of the adenoviral capsid allows
interaction of virions with cellular av intergrins, enhancing
glioma transduction.33 Moreover, combining the integrin
targeting of Ad vectors with their transcriptional targeting
by placing the E1 genes under transcriptional control of
tumor-specific (survivin34 or telomerase35) promoters
(TSPs), or mutations (delta24) in E1 genes that abrogate
their binding to Rb or p53 can further improve specificity
and efficacy of glioma targeting.36e42
Another type of genetic modification that redirects Ad
particles to alternate receptors is incorporation of a poly-
lysine motif at the C-terminus of the fiber protein. While
this modification does not ablate CAR-mediated binding and
internalization of viral particles, it improves Ad infectivity
through a positively-charged heparan sulfate proteoglycan
(HSPG) molecules abundant on the surface of cancer
cells.33 Zheng et al. tried to determine which of the HSPG
receptors is needed for transduction using pK7-modified Ad
vectors. Treatment of glioma cells with pK7-modified Ad
vector in the presence of neutralizing antibodies against
syndecan 1 and perlecan decreased efficiency of the cells
transduction by 30e50%, implicating those molecules in
attachment to the Ad5pK7 virus. The first Ad vector tar-
geted to HSPGs through incorporation of 7 lysine amino
acids (heptalysine) into the C-terminal domain of the wild
type Ad5 fiber was designed by Wickham et al.43 The
attachment of Ad particles to the target cells can be
significantly augmented given that the viral capsids retain
capability of binding to CAR, typically expressed by rapidly
proliferating cells, as well as to cellular integrins through
an RGD motif in the penton base. However, these receptors
are also expressed on muscle cells, macrophages, and
endothelial cells, making them a less desirable transduction
targets.43 Although most cancer cell lines are highly
permissive for Ad vector transduction, its efficiency in
patient-derived primary tumor cells is rather poor. To
further improve gene transfer of Ad5 vectors enhanced by
RGD-4C or pK7 fiber modifications, the viral tropism could
be expanded to additional set of receptors, not used by
group C species. This can be achieved by using a small
peptide/ligand (RGD-4C) modification in the context of Ad3
fiber pseudotyping.44 Although studies using the replication
deficient (DE1) Ad5/3-RGD vector showed a great promise
for gliomas,44 the benefit of this combined fiber modifica-
tion for GBM oncolytic virotherapy is yet to be determined.
Expression of EGFR localized to the cell surface is
upregulated in 40e60% of gliomas.45 Transductional tar-
geting of the EGFR receptor was first proposed by Grill
et al., in 2001.46 Ad5 particles can be re-directed to this
receptor by a bi-specific single chain antibody (scFv)expressed from either E1 or E4 regions of the Ad5 genome
that would bridge the fiber knob and the EGFR receptor on
the target cell surface. However, retention of the CAR-
binding site within the genetically-unmodified (WT) Ad5
fiber knob could interfere with the cancer specificity of
transduction due to the potential ability of the scFv-
complexed Ad5 to simultaneously recognize CAR receptor
on the surface of non-cancer cells. Although, incorporation
of 425-S11 single chain antibody into the fiber knob domain
improves transduction of CAR-negative tumors by 2- to 11-
fold,46 further ablation of the native CAR tropism is
required. For instance, redirection of adenoviral particle to
EGFR with simultaneous ablation of CAR and av integrin
binding ability provides selective gene transfer to glioma
cells.47 These promising results led investigators to design
an 435-S11 scFv-modified CRAd48 to target and destroy CAR-
deficient tumors. The mutant version of EGFR (EGFRvIII) is
present on the majority of glioma cells as well as breast and
ovarian cancer cells49 and regulates pro-survival pathways,
which makes it a promising candidate for cancer gene
therapy.50
In conclusion, the data published by Nandi et al.30 sug-
gest that retargeting Ad particles by genetic pseudotyping
of fiber can greatly improve CRAd cytotoxicity for tumors.
However, in many cases tumor-specificity of such Ad vec-
tors remains poor since the alternate receptors such as
CD133 (expressed on the surface of glioma stem cells and
neural stem cells) and CD46 they are often retargeted to,
are also found on the surface of non-cancer cells. There-
fore, further capsid modifications are needed to optimize
CRAds for cancer gene therapy.Limiting adenovirus transcription to glioma
cells
Genetic incorporation of tumor-associated gene expression
control elements into the Ad genome for regulating its early
(E1) gene expression (transcriptional or post-
transcriptional), improves CRAd vector specificity by
restricting viral replication to tumor cells, and thereby
preventing unfavorable vector toxicity in normal cells. To
achieve this specificity, incorporation of transcription fac-
tor recognition motifs and/or microRNA binding elements
upstream of the Ad5 E1 genes has been proposed. The
rationale behind this approach was to provide conditional
(selective) expression of the E1A protein, crucial for trig-
gering Ad early gene transcription and genomic DNA repli-
cation. A prototypical tumor-specific promoter (TSP) is
known from the literature to selectively regulate/activate
Ad early gene expression in tumor cells, yet remain inactive
in healthy tissues, such as liver, involved in efficient uptake
of most Ad5 entering the circulation. The “tumor on/liver
off” expression ratio is a commonly accepted tumor-
specificity characteristic of a TSP.
Recently, Guvenc et al., showed that tumor cells highly
resistant to therapy exhibit high expression level of the
survivin gene.51 The latter codes for an anti-apoptotic
protein that governs spindle formation and chromatin sep-
aration during tumor cell mitosis.51e53 The high level of
survivin protein correlates with high level of its mRNA,
suggesting activity of the survivin promoter and stability of
CRAd for glioma therapy 219its mRNA in those cells. Aw200 bp fragment of the survivin
promoter (short version) was found to be sufficient to
confer Ad replication specificity to glioma cells.34,54 More-
over, since the survivin promoter contains radiation-
inducible elements, ionizing radiation can sensitize
exposed glioma cells to infection by survivin-E1 bearing
CRAd vectors.55
Midkine (MK) is a heparin-binding growth factor encoded
by the MDK gene. Induced during ontogenesis and inflam-
mation, syndecan 1 is the midkine receptor regulating cell
proliferation, angiogenesis, fibrinolysis, and mRNA expres-
sion in several cancers including glioblastoma and neuro-
blastoma. Since MK is implicated in cancer cell
proliferation, it has become a target for gene therapy.
However, there are also effects of MK on genesis of normal
cells such as fibroblasts, myoblasts, and renal cells,56 and
therefore cancer specificity of CRAd vectors with MK
promoter-controlled replication is questionable. Never-
theless, an oncolytic vector with a w600 bp MK promoter
element, driving expression of adenoviral E1A, has been
demonstrated to eradicate MK-positive glioma cells in vitro
and in vivo.57
The Promoter of the telomerase related gene (TERT ) is
also active in glioma cells. According to scientific litera-
ture, more than 85% of cancers express telomerase, which
is required for cell proliferation. A 455 base pair (bp) pro-
moter of the human gene, coding for the telomerase cat-
alytic subunit, was successfully used for construction of
OBP-301 CRAd (also known as Telomelysin)
transductionally-retargeted to intergrins on glioma cell
lines U87, U373, U251, and patient-derived MDC-01.35
However, not all glioma cells exhibit high telomerase ac-
tivity. For instance, according to studies by Jafri et al., only
26.1% of high-grade glioma specimens exhibit high telo-
merase activity.58,59 Under certain conditions, normal cells,
such as fibroblasts, possess very low levels of telomerase
activity, which, however, could be induced by drugs, such
as HDAC.60,61 This data points to some limitations for tar-
geting primary tumors in clinical settings.
Another study conducted by Hoffmann et al evaluated
potential glioma-specific promoters for oncolytic virother-
apy including those of VEGF, GFAP, FGF, Ki-67, Nestin, and
Midkine gene alone, or in combination with an SV40 pro-
moter/enhancer.62 According to this data, elevated activity
of promoters was manifested by expression of the Lucif-
erase reporter. Based on this assay conducted in several
patient-derived and established glioma cell lines (D54,
U251, and U87), the top 7 promoters included: MK, hTERT,
VEGFlong, VEGFshort, Ki67, GFAP, and E2F/SV40. Further-
more, in vitro promoter activity testing showed that the
long version of the human GFAP promoter restricts repli-
cation of the CRAd5/35 vector to glioma cells with both
high and low level of proliferation capability. Those in vivo
data corroborate the ones in vitro and suggest that GFAP
promoter-controlled CRAd prolongs survival of mice
harboring fast growing U251 xenografts. A study performed
by Horst et al.63 showed that rapidly dividing glioma cells
can be targeted by a CRAd vector with GFAP promoter-
controlled replication. Since GBM cells are sensitive to
ionizing radiation and temozolomide treatment, virother-
apy with the GFAP promoter-controlled CRAd could be used
to augment current therapeutic modalities.Tumor selective transcription: is CMV
promoter the best reference?
Several studies have compared efficiency of various pro-
moters against that of CMV. A study by Zheng et al.64
demonstrated that replacement of the E1A gene promoter
with the CMV major late promoter (MLP) failed to provide
cancer specificity to Ad replication. Furthermore, utiliza-
tion of the CMV promoter to control CRAd replication (E1
transcription) resulted in lower replication efficiency as
compared to the native (E1) promoter-bearing CRAd in
OE33 and OsACL cancer cell lines. In contrast, equal levels
of CRAd replication resulted from the CMV-driven E1
expression and the one controlled by the native promoter in
A549 (lung adenocarcinoma cells), or WI-38 non-tumor
cells. These observations suggest that the CMV promoter
does not confer tumor-specificity to CRAd replication.
Similar results were also obtained in other studies.65 To
date, experimental evidence suggests that most tu-
mors,66,67 including brain tumors,68e70 contain cytomega-
lovirus proteins, DNA and RNA transcripts, particularly the
ones of the early and immediate early CMV genes. Besides
its robust activity in tumors, the CMV MLP promoter is also
active in normal cells, which reduces specificity of CRAd
vectors utilizing this promoter to control expression of the
E1 genes.
Recent reports have indicated that glioma resistance to
conventional treatment modalities may be determined by
expression of therapy-resistant proteins, such as the Y-box
protein YB-1, a cellular transcription factor implicated in
GBM cell survival.71,72 Treatment of cells with UV radiation
and chemotherapy translocates YB-1 from the cytoplasm to
the nucleus, indicating its possible role in DNA repair.73,74
Since expression of multidrug-resistance genes correlates
with YB-1 activity, it is logical to expect a YB-1-dependent
CRAd to selectively replicate in chemo-resistant glioma
cells. In line with this expectation a YB-1-dependent CRAd
dl520 (DE1A-13S) demonstrated oncolytic activity in glioma
cells, resistant to Irinotecan and Trichostatin A.75 Most
recently, a dl520-derivate Ad-Delo3-RGD, carrying an
additional E1B gene deletion and the integrin binding motif
in the fiber protein, also demonstrated a selective repli-
cation in chemo-resistant glioma stem cells.76
The other genetic alteration in gliomas that impacts cell
division is p16INK4a, leading to phosphorylation of Rb and
activation of E2F1 transcriptional factor.77 To restrict
expression of the adenoviral E1A protein to target (glioma)
cells deficient in the Rb pathway, authors placed E1A
transcription under control of endogenous E2F1 transcrip-
tion factor by cloning an E2F1 response element in place of
the E1 promoter region.42 As a result, replication of such
CRAd (ICOVIR5) in normal cells with low level of free E2F1
(trapped in the form of Rb/E2F1 inactive complex) was
suppressed. On the contrary, an excessive amount of E2F1
in glioma activated ICOVIR5 vector’s replication in target
cells. Thus, replication activity of this CRAd directly cor-
relates with the E2F1 expression in the virus-infected
cells.78 However, since high level of E2F1 expression is a
feature characteristic for any rapidly dividing cells,79 the
E2F1-controlled CRAd vector cannot discriminate between
rapidly dividing normal cells and malignant cells.
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transcriptional level involving microRNA (miRNA), found in
gliomas, can also be utilized in gene therapy approaches.
MicroRNAs are small non-coding RNAs complimentary to
target cellular mRNAs. MicroRNA binding to target mRNA
leads to specific repression of regulatory genes either on
transcriptional or translational levels. It is well documented
that gliomas exhibit diverse microRNA expression patterns
or “signatures”. Given that miRNAs can regulate cell pro-
liferation, invasion and angiogenesis, incorporation of
miRNA coding sequences into CRAds could aid to CRAd’s
cytotoxic activity. It was recently shown that glioma cells
express high levels of microRNA 124,-128,-146B and 218,80
and therefore incorporation of microRNA recognizing ele-
ments (MREs) into the Ad genome could inhibit CRAd
replication in tumor tissues. It remains to be investigated
whether the microRNA-mediated CRAd targeting approach
will be efficient in human tissues with regard to patient’s
age, and the course of treatment as those might affect
miRNA expression.
Analysis of scientific literature suggests that cancer
specificity of CRAd agents can be achieved by proper se-
lection of transcription regulatory elements and their ge-
netic incorporation in CRAd genomes to control viral E1
transcription. However, despite strong antitumor effects,
incorporation of a given TSP may not prevent E1A tran-
scription leakage from the inverted terminal repeat (ITR)
sequences in the Ad genomic DNA.81 For instance, previous
studies have shown that multiple enhancer elements and
cryptic promoter elements exist within the Ad ITRs, which
can contribute to undesired “leaky” E1 transcription in
healthy cells.64,82,83
Strategies to improve anti-glioma efficacy of
CRAds
As it was mentioned above, glioma cell populations
responsible for tumor recurrence exhibit strong resistance
to conventional treatment modalities. Therefore, it is
critical to find a new and more effective therapeutic
approach devoid of cytotoxicity caused by the conventional
anti-glioma treatments. Besides, a growing body of evi-
dence suggests that intratumoral injection of CRAds acti-
vates antiviral immune response. To circumvent the
immune response problem various Ad shielding methods,
such as coating with polyethylene glycol (PEG) or using
stem cells as Ad delivery vehicle, have been developed.
a) Strategies to improve CRAd-mediated toxicity: RT and
chemotherapeutic drugs.
In has been shown that chemotherapeutic agents acti-
vate cellular pathways that contribute to CRAd-mediated
toxicity. We54,84,85 and others86e91 have shown that CRAds
induce cell death via two main mechanisms: apoptosis, and
autophagy. Despite activation of pro-apoptotic genes, such
as BAX2, BIM, and BIK, CRAd infection does not trigger
caspase-dependent apoptosis. Several reports suggest that
CRAds induce autophagy, which involves the formation of
double-membrane phagosomes. Moreover, recent evidence
suggests that the E4 region of the Ad genome is required toinduce autophagy upon the viral infection. Augmentation of
CRAd-induced autophagy is one strategy to boost CRAd
toxicity. Ionizing radiation,36,40,55,89 RAd00135,39 and clini-
cally approved temozolomide (TMZ)35,38,76,92 have been
utilized to promote CRAd-mediated autophagy. However, it
is, still unclear whether this effect can be directly attrib-
uted to CRAd, or is merely a result of CRAd-induced cell
defense mechanism that requires more inhibition to
improve CRAd cytotoxicity.
b) Sensitization of cells to the CRAd-mediated toxicity
using TRAIL and CD gene expression
To successfully design and develop effective treatments
for GBM, combinational approaches to targeting several
molecular pathways may be necessary. Despite our
advancing knowledge of the genetic alterations involved in
this disease, identification of new therapeutic combina-
tions may prove advantageous. To augment CRAd-mediated
toxicity, expression of pro-apoptotic molecules, such a
TRAIL (TNF-related apoptosis-inducing ligand), represents a
new anti-glioma approach. TRAIL represents an extracel-
lular carboxy-terminal portion of the type II trans-
membrane protein that sensitizes tumor cells to apoptosis
via binding to the DR4 (DR5) receptor. This, in turn, acti-
vates caspase 8/10 or the intrinsic cytochrome C release
pathway, which subsequently activates SMAC/DIABLO to
translocate pro-apoptotic BIK, BID and BAX.93e96 The com-
mon activation of BAX and suppression of anti-apoptotic
BCL-2 apparently provides a mechanistic link for the addi-
tive effect between CRAd and TRAIL expression.97e99 Wol-
hardt et al.31 first proposed targeting glioma cells with the
CRAd-TERT-5/35 vector encoding TRAIL as a therapeutic
transgene, while expressing proteins of the E1 region under
control of the human telomerase promoter. In addition, the
capsid of this vector was retargeted to an alternate re-
ceptor by replacing the wild type fiber knob domain with
that of serotype 35. Later, this approach was elaborated by
Li et al.,32 who used a delta24-5/11 backbone, and by
Tsamis et al.,100 who used a delta24 backbone with the WT
fiber. In all cases, expression of TRAIL in the context of an
oncolytic vector resulted in strong anti-cancer effect
compared to the unarmed CRAd.
In 2005 Conrad et al.101 attempted to combine an
oncolytic Ad vector and pro-drug therapy to suppress gli-
omas. In addition to the oncolytic effect the virus elicited
cytotoxicity owing to the expression of the delivered “sui-
cide” gene (humanized form of yeast cytosine deaminase,
hyCD) converting 5-FC substrate to a toxic metabolite 5-FU
in tumor cells.102 Given the limitation in achieving an
effective therapeutic dose without hepatotoxicity in the
U87 intracranial glioma mouse model, delivery of pro-drug
therapy in the context of an oncolytic vector holds a
great promise.
c) Modification of CRAd genome to improve CRAd-mediated
cytotoxicity.
The adenoviral genome encodes immediate early and
early genes transcribed before the onset of DNA replica-
tion, as well as late genes transcribed after DNA replica-
tion. The functions of the Ad5 early proteins include:
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responses to Ad infection, preventing apoptosis (E3) and
activation of Ad replication91 (E2). The E3 genes encode 7
proteins, including adenoviral death protein (ADP), which is
exclusively expressed during the late stage of infection103
and is responsible for efficient cell lysis and progeny
release.104 In efforts to improve adenoviral oncolysis Yun
et al. designed an anti-glioma CRAd that harbors a 55Kda-
E1B deletion and expresses ADP under the control of the
adenoviral Major Late Promoter (MLP) or CMV promoter.91
The vector expressing a CMV-driven ADP exhibited a
strong cytotoxicity towards human U343 glioma cells.
Although, in vitro data suggest that w40% of glioma cells
were sensitive to infection with ADP-overexpressing CRAd,
this observation has not been confirmed in vivo. Taken
together, all this data suggest that overexpression of ADP
facilitates CRAd-mediated oncolytic effect.
d) Improvement of CRAd-mediated toxicity by indirect
activation of viral replication in the presence of hypoxia.
One of the disadvantages of using adenoviral vectors in
cancer gene therapy is uneven dissemination of the vector
across the tumor mass.105 One study showed that hypoxia
may compromise blood supply to certain regions of tumor
tissue, which ultimately limits intratumoral distribution of
CRAds.106 Given that hypoxia contributes to GBM invasion
and proliferation by maintaining its CSC component,107e109
targeting GBM CSCs via accelerating CRAd replication
under hypoxic conditions may improve anti-glioma ther-
apy. It has been shown that hypoxia affects tumor pro-
gression through the blood, and regulates activity of target
genes via binding of hypoxia induced-transcription factors
to hypoxia response elements (HRE). These transcriptional
regulators allow cells to survive hypoxia by activating
proliferation.110 Therefore, CRAds designed to aggressively
replicate in hypoxic environment by utilizing hypoxia-
inducible factors (HIF) to control their replication may
be effective in suppressing gliomas108 In line with the
above Post et al demonstrated that incorporation of HRE in
the E1 region improved CRAd replication in hypoxic areas
of tumors.111
e) Strategies to modulate the anti-Ad immune response?
It is known that patients with GBM develop a strong
immunosuppression resulting from chemotherapeutic
drugs, ionizing radiation, accumulation of cancer stem
cells, etc. This evidence has initiated the debate as to
whether brain tumor patients might benefit from immune
system stimulation through experimental therapies, such as
gene therapy with CRAds, which have been shown to induce
a proinflammatory response in glioma mouse models. Since
the mechanism of antitumor effect achieved by glioma
virotherapy is still unclear, it cannot be ruled out that
modulation of the patient’s immune response might
strongly interfere with the effectiveness of the treatment.
A recent publication by Liikanen et al.112 reignited discus-
sions about the role of immune system activation in CRAd-
mediated tumor oncolysis. Considering that immune
response to Ad vector could significantly compromise theefficacy of CRAd-mediated tumor oncolysis by rapid
clearing of the viral particles, the overall impact of immune
response on the clinical outcome of glioma virotherapy
treatment is still in question.
The immunological responses to CRAd infection has been
investigated by several research groups. One study using
immunosuppressed hamsters suggested that the host im-
mune response neither significantly contributes to CRAd
clearance, nor to the antiviral immune response.113 More-
over, steady levels of the virus were detected in immuno-
suppressed hamsters, similar to those found in mouse
xenografts. In immunocompetent animals, the level of
CRAd dropped 22 days after tumor implantation, suggesting
activation of viral clearance. In this regard, of interest is a
recent data from Klejin et al.114 demonstrating that the
immune response to delta24-RGD affects therapeutic effi-
cacy in the rodent immunocompetent glioma model. In
fact, a local production of proinflammatory cytokines in
response to intratumoral vector injection increased along
with the number of infiltrating CD4þ and CD8þ lympho-
cytes and macrophages. It still needs to be determined
whether the observed immune response was activated due
to the host’s protective response against CRAd replication,
or was a result of the viral mechanism contributing to its
replication.
The main role of stem cell-based vectors is to preserve
and deliver CRAds to tumors in tumor-specific fashion,
while avoiding activation of anti-Ad immune responses.
Delivery of CRAd payloads to tumors and passing those
payloads on to neighboring cancer cells within the tumor
mass by means of GSCs is based on their intrinsic tumor
homing properties. Glioma cells release chemokines and
angiogenic factors, such as TGF-b,115 PDGFb,116 VEGF,117
which attract stem cells administered via various routes.
Indeed, the bone-marrow-derived mesenchymal stem cells
(MSC) have been reported to improve CRAd persistence and
dissemination in vivo.118,119 Moreover, a delta24 CRAd MSC-
delivered to glioma xenografts, significantly prolonged
mice survival in glioma xenografts.120 Of note, regardless of
the delivery route, intravenous,115 or intracranial (delivery
of payload from one brain hemisphere to another hemi-
sphere bearing a tumor), MSC successfully targeted glioma
xenografts. Similarly, we have shown that HB1.F3.CD NSCs,
which lack HLA class I antigen, when loaded with the CRAd-
S-pK7 vector, exhibit a robust anti-glioma effects in vitro
and in a U87 intracranial mouse model121 A side-by-side
comparison between the MSC (mesenchymal stem cells)-
and NSC (neural stem cells)-based CRAd delivery cell vec-
tors showed that the NSC delivery system is more advan-
tageous.122 One significant disadvantage of using NSCs for
targeted CRAd delivery is their sensitivity to CRAd infec-
tion, which prevents effective migration and delivery of
CRAd payload to other sites within the tumor due to CRAd
leakage. To circumvent this drawback Kim et al.123 utilized
N-acetylcysteine (NACA) for treatment of NSCs loaded with
CRAd-S-pK7 to attenuate the CRAd-induced apoptosis. The
NACA-treated loaded NSCs lived longer and maintained
properties necessary to deliver their payload. Although
these results suggest that stem cells improve CRAd distri-
bution in vivo, the use of immunocompromised animal
models makes it difficult to assess the induction of an
antiviral immune response.
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Although the efficacy of CRAd delivery to glioma is a critical
factor of the experimental therapy, safety of the treatment
is of high importance too, especially since ongoing in-
vestigations emphasize the role of new etiological agents in
glioma progression. CRAd safety testing has been per-
formed in vitro using human culture of healthy adult as-
trocytes30,124,125 or cultured fibroblasts63,75,91,126 and
in vivo, using animal models for neurotoxicity testing. As
can be seen from the data summarized in Table 1, human
non-malignant cells exhibit various sensitivities to CRAd
infection, which is important to assess prior to in vivo CRAd
testing in glioma animal models. A preliminary survival
experiment in the form of a brain neurotoxicity test, using
CRAd intracranially implanted into mice brain at lowest and
highest doses, is recommended to determine the maximum
tolerated dose (MTD) of the viral vector. Since mice are not
permissive for human Ad replication as opposed to hamsters
or cotton rats, those rodents represent better animal
models for neurotoxicity testing.
The use of NSCs to deliver a CRAd payload requires
safety testing as well. An important study by Aboody et al.
showed that HB1.F3.CD NSCs (which lack HLA class I anti-
gen) are non-tumorigenic after activating CD gene expres-
sion by pro-drug 5-fluorocytosine (5 FC).127 Considering that
cytomegalovirus was found to persist in NSCs,128 it is
important to assess the risk of stem cells application for
patients. In case of high permissiveness, addition of 5FC or
any other cytotoxic agent would eliminate the stem cells
but may not kill cytomegalovirus harbored by those cells.
Moreover, recent data suggest that the presence of cyto-
megalovirus may impact activation of pro-tumorigenic
adenoviral regions, such as E1A.129 Of note, it has been
shown that E1A genes under certain conditions may elicit
formation of oncogenic fusions130 and form tumors in
newborn hamsters131,132 Therefore, it is highly unlikely, but
still possible that CMV-mediated protein expression (IE1)Table 1 Comparative toxicity of CRAd vectors.
Cell type/sell type system Vendor Method to
specificity
Human
astrocytes
Adult primary astrocytes Lonza LDH
Lonza Crystal vi
and CRAd
Lonza Progeny t
Human
fibroblasts
Fetal lung fibroblasts MRC5 ATCC Ad replica
Dermal fibroblasts Hs68 ATCC Cytopathi
microscop
Normal skin fibroblasts BJ ATCC Crystal vi
Normal skin fibroblast BJ;
fung fibroblasts IMR90;
lung fibroblasts WI38
ATCC Crystal vican trans-activate E1A to produce tumorigenic phenotype
in stem cells. From a therapeutic standpoint, it remains
unclear whether NSC passage can affect efficacy of CRAd
delivery, as well as whether aged stem cells are capable of
inducing tumor formation.
Concluding remarks and future directions
Obtaining an FDA approval for the use of CRAd vectors in
human clinical studies requires significant time and efforts
from investigators. Although in many cases in vitro data
obtained from tumor clinical samples and in vivo data from
mouse xenograft models look very promising, a single mo-
dality treatment is often less effective than a combination
of other therapeutic approaches. Moreover, recent studies
suggested that inflammation and immune response might
affect efficacy and specificity of CRAds as anti-glioma
agents. Although various immunomodulation strategies
have been suggested, which involve either genetic modifi-
cations of the Ad genome to suppress anti-Ad immune
response, or shield viral particles from the immune system
by means of coating with molecular polymers or loading
inside GSC as vector delivery vehicles, they all require
additional experimental evaluation. Finally, the established
role of autophagy in promoting Ad-mediated oncolysis and
suppression of the host immune response to Ad will help
determining the marker of cell resistance controlling anti-
viral response at the cellular and organismal levels. It re-
mains unclear whether delivery of anti-angiogenic or
immunomodulatory factors by Ad vectors actually improves
oncolytic effect in patients with brain tumors. This data
need to be analyzed in the future. Although oncolytic ad-
enoviruses alone demonstrate a substantial anti-glioma
potency in vitro and in vivo, recent studies suggest that
the combination of virotherapy with chemotherapy and/or
immunotherapy may provide greater therapeutic benefit.
Therefore, tackling glioma progression from different di-
rections, i.e. by utilizing a combination of immunotherapy,
angiogenic therapy, oncolytic virotherapy, radiotherapy,detect CRAd
/toxicity
Cytotoxic dose of
CRAd/effect
Reference
10 vp per cell/w25%
dead cells
30
olet toxicity test
replication
10 vp per cell/w90%
toxicity
124
itration 10 MOI per cell/CRAd
replication from 1.9  102
to 1  106
125
tion ratio to AdWT 0.1 MOI per cell/0.2-0.5 63
c effect, light
y
50 MOI per cell 75
olet toxicity test Various toxicity from 10
to 0.01 MOI per cell
91
olet toxicity test Various toxicity from
100 till 10 MOI
126
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